SAN DIEGO, March 12, 2014 -- Fate Therapeutics, Inc. , a biopharmaceutical company engaged in the discovery and development of adult stem cell modulators to treat orphan diseases, announced today the enrollment of the first patient in its "PUMA" study, a Phase 2 clinical trial of Prohema using the Company's nutrient-rich media formulation.
http://ift.tt/1m1X1Ud?
http://ift.tt/1m1X1Ud?
No comments:
Post a Comment